Gross Profit Comparison: United Therapeutics Corporation and BioMarin Pharmaceutical Inc. Trends

Biotech Giants' Profit Surge: A Decade of Growth

__timestampBioMarin Pharmaceutical Inc.United Therapeutics Corporation
Wednesday, January 1, 20146212760001162636000
Thursday, January 1, 20157378870001396725000
Friday, January 1, 20169072340001526100000
Sunday, January 1, 201710718600001619600000
Monday, January 1, 201811759480001429100000
Tuesday, January 1, 201913445820001331200000
Wednesday, January 1, 202013361830001375200000
Friday, January 1, 202113757600001563000000
Saturday, January 1, 202216123700001789600000
Sunday, January 1, 202318421610002070000000
Monday, January 1, 20242273680000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Growth: United Therapeutics vs. BioMarin Pharmaceutical

In the ever-evolving landscape of biotechnology, United Therapeutics Corporation and BioMarin Pharmaceutical Inc. have emerged as formidable players. Over the past decade, from 2014 to 2023, both companies have demonstrated impressive growth in gross profit, reflecting their strategic prowess and market adaptability.

United Therapeutics has consistently outperformed BioMarin, with a gross profit increase of approximately 78% over this period. Starting at $1.16 billion in 2014, it soared to $2.07 billion by 2023. Meanwhile, BioMarin's gross profit grew by nearly 197%, from $621 million to $1.84 billion, showcasing its robust expansion strategy.

This financial trajectory highlights the dynamic nature of the biotech industry, where innovation and strategic investments drive substantial growth. As these companies continue to innovate, their financial performance will be a key indicator of their future success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025